As research into drug allergies aims at informing clinical practise, the use of best practises may be affected by financial capital necessary to integrate novel intervention and the potential clinical and economic return on investment. The present analysis brings together new perspectives into drug allergy’s economics over the last year. While several studies considered the economic impacts of recent research into medication allergies, varying contexts relative to the environment, supplier, or results were discussed. Advances of technologies have made it possible for allergists specialising in telemedicine to serve remote environments. Training opportunities and interdisciplinary approaches to the complexities of drug allergies have enabled many categories of providers to play a part in the testing, evaluation and administration. Penicillin allergy research was an important priority for many organisations, including confirmatory skin testing and direct oral challenges, with a number of trials focusing on de-labeling techniques.

Over the past year, studies have provided new avenues for investigations into drug allergies. Present studies aimed at identifying direct treatment costs or gains from treatments including opioid allergy shows the possibility of improving cost-effective health coverage and exploring wider societal benefits.